英文名:Research grade Atezolizumab Biosimilar, Mouse IgG2a L234A L235A P329G (LALAPG) Fc Silent Mutant 供货商名称:Syd Labs, Inc. 公司名:Syd Labs 别称:程序性死亡配体1,PD-L1,分化簇274,CD274, B7同源物1,B7- h1 概述:研究级Atezolizumab生物类似药蛋白(research grade Atezolizumab biosimilar protein...
To examine the tumor growth inhibitory activity of the Anti-PD-L1 antibody drug, mice were first injected subcutaneously with mouse colorectal tumor MC38 cells. On day 7, the animals were randomly grouped into four groups with 8 mice per group. Placebo or antibody drugs were administered to th...
triple-negative breast cancer patients improved tumor infiltration of mature DCs and effectorT cells(Boucher et al., 2021). In mouse tumor models, anti-VEGF treatment resulted in more mature DCs and less exhausted T cells intratumorally as well as reprograming of immunosuppressive M2-like ...
Atezolizumab but not durvalumab binds and blocks mouse PD-L1. Note Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use. Order Of...
Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model Atezolizumab (a PD-L1 inhibitor) has shown remarkable efficacy and tolerability in various cancer types. Despite its efficacy and safety, atezolizumab mono... SY Yang,J Yi...
In mouse models of cancer, dual inhibition of the PD-1/PD-L1 and MAPK pathways suppresses tumor growth and improves tumor immunogenicity through increased antigen presentation and T cell infiltration and activation compared to targeted therapy alone. Pharmacodynamics The exposure-response relationship and...
In addition, it has also been shown preclinically in invivo mouse non-small cell lung carcinoma (NSCLC) models that inhibition of Gal-3 enhances the performance of checkpoint inhibitors targeting the PD-1/PD-L1 axis (Vuong etal., Cancer Res, 2019; Zhang etal., FEBS Open Bio, 2020). ...
In mouse models of cancer, dual inhibition of the PD-1/PD-L1 and MAPK pathways suppresses tumor growth and improves tumor immunogenicity through increased antigen presentation and T-cell infiltration and activation compared to targeted therapy alone. Hyaluronan is a polysaccharide found in the extracel...
Mouse monoclonal antibody raised against Atezolizumab. Target gene is PD-L1. Immunogen Atezolizumab. Host Mouse Specificity The product is specific for Atezolizumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody Anti-Atezolizumab monoclon...
In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials. Recently,